About roche holding ag - RHHVF
Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
RHHVF At a Glance
Roche Holding AG
Grenzacherstrasse 124
Basel, Basel-Stadt (Basle Town) 4058
| Phone | 41-61-688-11-11 | Revenue | 74.07B | |
| Industry | Pharmaceuticals: Major | Net Income | 15.51B | |
| Sector | Health Technology | 2025 Sales Growth | 7.832% | |
| Fiscal Year-end | 12 / 2026 | Employees | 112,774 | |
| View SEC Filings |
RHHVF Valuation
| P/E Current | 20.231 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 21.262 |
| Price to Sales Ratio | 4.491 |
| Price to Book Ratio | 7.725 |
| Price to Cash Flow Ratio | 15.49 |
| Enterprise Value to EBITDA | 13.202 |
| Enterprise Value to Sales | 4.862 |
| Total Debt to Enterprise Value | 0.116 |
RHHVF Efficiency
| Revenue/Employee | 656,820.444 |
| Income Per Employee | 137,522.715 |
| Receivables Turnover | 4.181 |
| Total Asset Turnover | 0.619 |
RHHVF Liquidity
| Current Ratio | 1.383 |
| Quick Ratio | 1.116 |
| Cash Ratio | 0.553 |
RHHVF Profitability
| Gross Margin | 73.534 |
| Operating Margin | 31.315 |
| Pretax Margin | 27.593 |
| Net Margin | 20.938 |
| Return on Assets | 12.954 |
| Return on Equity | 39.91 |
| Return on Total Capital | 18.341 |
| Return on Invested Capital | 20.771 |
RHHVF Capital Structure
| Total Debt to Total Equity | 98.192 |
| Total Debt to Total Capital | 49.544 |
| Total Debt to Total Assets | 32.959 |
| Long-Term Debt to Equity | 84.829 |
| Long-Term Debt to Total Capital | 42.801 |
Roche Holding Ag in the News
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Inside the race for a COVID-19 treatment pill
Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.